Stereotaxis (NYSEAMERICAN:STXS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Stereotaxis (NYSEAMERICAN:STXS) issued its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02), Zacks reports. The company had revenue of $8.93 million during the quarter, compared to analysts’ expectations of $9.60 million. Stereotaxis had a negative return on equity of 144.02% and a negative net margin of 70.86%.

Here are the key takeaways from Stereotaxis’ conference call:

• GenesisX and Synchrony are beginning to contribute to capital sales. Stereotaxis reported a pipeline of a couple dozen GenesisX opportunities and about 50 Synchrony systems; the company expects upcoming GenesisX installations and new X-ray compatibility, including a collaboration with Canon, to support broader adoption.
• MAGiC catheter supply remains a major constraint. Osypka’s production did not increase in the third quarter, leaving about $1.9 million of disposable orders unfilled entering Q4. Stereotaxis expects supply relief in early 2027, pending regulatory milestones for an alternative supply source, and said the shortage continues to limit procedures and recurring revenue.
• Third-quarter revenue rose 20% year over year to $8.9 million, while recurring revenue increased 6% to $5.9 million but fell 4% sequentially. Gross margin was 45%; operating and net losses were both $6.5 million, and adjusted operating expenses increased from a year earlier, partly due to Robocath-related costs.
• Stereotaxis received $12 million upfront through a convertible-note financing and has the option to draw another $12 million after a regulatory milestone. The company said pro forma cash is $16 million, with up to $28 million available, and management sees a path to profitability next year as recurring revenue grows and capital sales become more consistent.

Stereotaxis Stock Performance

Shares of STXS opened at $0.90 on Thursday. Stereotaxis has a one year low of $0.80 and a one year high of $2.86. The stock has a market capitalization of $89.68 million, a price-to-earnings ratio of -3.72 and a beta of 1.40. The stock has a 50 day moving average price of $1.15 and a 200 day moving average price of $1.65.

Analyst Ratings Changes

STXS has been the topic of several research analyst reports. Citigroup reiterated an “outperform” rating on shares of Stereotaxis in a research report on Thursday, August 27th. TD Cowen reduced their price target on shares of Stereotaxis from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Citizens Jmp decreased their price target on shares of Stereotaxis from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 27th. Four research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $2.83.

Stereotaxis Company Profile

Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular procedures, with a primary focus on cardiac electrophysiology. Its systems use magnetic navigation and specialized software to help physicians control guidewires and catheters during procedures such as the treatment of cardiac arrhythmias. The company’s product portfolio includes the Genesis Robotic Magnetic Navigation System, which is designed to provide precise catheter movement and navigation within the heart.